Personalized medicine

Personalized medicine proposes customization of healthcare - with medical decisions, practices, and/or...

Personalized medicine proposes customization of healthcare - with medical decisions, practices, and/or products being tailored to the individual patient - such as by use of genetic or other information.Report: Personalized Medicine Partnering Terms and Agreements

Report: Biomarker Partnering Terms and Agreements

Report: Companion Diagnostics Partnering Terms and Agreements

Report: Pharmacogenomic Partnering Terms and Agreements

Personalized medicine proposes customization of healthcare - with medical decisions, practices, and/or products being tailored to the individual patient - such as by use of genetic or other information.

Personalized medicine tools provided to the physician are more precise, probing not just the obvious, such as a tumor on a mammogram or cells under a microscope, but the molecular makeup of each patient.

Looking at the patient on this level helps the physician get a profile of the patient’s genetic distinction, or mapping.

By investigating this genetic mapping, medical professionals are then able to profile patients, and use the found information to plan out a course of treatment that is much more in step with the way their body works.

Genomic medicine and personalized medicine use genetic information to prevent or treat disease in adults or their children.

Personalized medicine may be able to help the medical community make the most effective clinical decisions for each patient on an individual level.

Personalized medicine can be sub-divided into three distinct areas where biopharmaceutical intervention is concerned:

  • Biomarkers
  • Companion diagnostics
  • Pharmacogenomics

Read: more on personalized medicine deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Personalized Medicine Partnering Terms and Agreements

Report: Biomarker Partnering Terms and Agreements

Report: Companion Diagnostics Partnering Terms and Agreements

Report: Pharmacogenomic Partnering Terms and Agreements

Example personalized medicine deal from Current Agreements life sciences partnering, M&A and financing deals database:

Collaboration agreement for personalized medicine

Gentris, Shanghai Insitutes of Preventative Medicine

Jun 22, 2012

Gentris Corporation has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine.

The goal of this USA-China collaboration is to create translational research and epidemiological projects, as well as training and education programs, focused on pharmacogenomics and clinical sample banking, which will drive innovation in drug development and improvements in patient care.   Through this collaboration, Gentris and the Shanghai Institutes of Preventative Medicine will work together to launch cutting-edge research projects to discover, develop, and validate new genomic biomarkers.

Gentris will take the lead to identify sponsors in the United States, e.g., pharmaceutical companies, for these personalized medicine projects while the Shanghai Institutes of Preventative Medicine will seek support from Chinese organizations.   The tuberculosis drug-induced liver injury pilot (TB DILI Study), conducted between Gentris, the Shanghai Institutes of Preventative Medicine, and a non-profit research institute in Research Triangle Park (RTP) serves as a model for USA-China collaborations.

In this study, investigators designed a common protocol and pooled their resources to investigate DILI among tuberculosis patients in three Shanghai hospitals.

By utilizing metabolomics and pharmacogenomics, they are evaluating biomarkers for early detection. Dr. Tong Zhou, Senior Director of China Initiatives for Gentris, is Co-Principal Investigator for the TB DILI Study and has significant experience in developing and managing collaborations between the United States and China.

Dr. Zhou has also drawn upon his extensive network in China to begin establishing a satellite laboratory for Gentris in Shanghai that complies with U.S. regulatory standards.   For this personalized medicine program, research studies and epidemiological projects will be designed for implementation in Shanghai based on sponsor needs.

Key targeted therapeutic areas include oncology, infectious disease, and chronic disease.

Training and education initiatives will also be created to bring U.S. quality standards to China including GLP, GCP, CLIA, and CAP. Gentris, the Shanghai Institutes of Preventative Medicine, and their collaborators will work with leading experts to develop workshops, courses, and a fellowship program to educate academic and industry scientists in China regarding best practices in the application of pharmacogenomics for drug development.

 

For more information about this and hundreds more personalized medicine deals:

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Report: Personalized Medicine Partnering Terms and Agreements

Report: Biomarker Partnering Terms and Agreements

Report: Companion Diagnostics Partnering Terms and Agreements

Report: Pharmacogenomic Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Report: Biomarker Partnering Terms and Agreements

Report: Companion Diagnostics Partnering Terms and Agreements

Report: Pharmacogenomic Partnering Terms and Agreements

Read: more on personalized medicine deals in pharma, biotech, life science partnering deal news, insights and glossary

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database - includes comprehensive coverage of all deals and alliances for the top 50 pharma companies – find out more

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Print Friendly, PDF & Email
cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif